Orion OYJ Shares Outstanding 2017-2024 | ORINY

Orion OYJ shares outstanding for the quarter ending June 30, 2024 were 0.281B, a 0.37% increase year-over-year.

  • Orion OYJ 2023 shares outstanding were 0.281B, a 0.19% decline from 2022.
  • Orion OYJ 2022 shares outstanding were 0.281B, a 0.03% increase from 2021.
  • Orion OYJ 2021 shares outstanding were 0.281B, a 0.03% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Orion OYJ Shares Outstanding 2017-2024 | ORINY

  • Orion OYJ 2023 shares outstanding were 0.281B, a 0.19% decline from 2022.
  • Orion OYJ 2022 shares outstanding were 0.281B, a 0.03% increase from 2021.
  • Orion OYJ 2021 shares outstanding were 0.281B, a 0.03% increase from 2020.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.2B
Takeda Pharmaceutical (TAK)$43.3B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.2B
Astellas Pharma (ALPMY)$18.2B
United Therapeutics (UTHR)$16.1B
Summit Therapeutics (SMMT)$14.7B
Neurocrine Biosciences (NBIX)$12.1B
Shionogi (SGIOY)$11.9B
Catalent (CTLT)$10.7B
Jazz Pharmaceuticals (JAZZ)$7.1B
Madrigal Pharmaceuticals (MDGL)$6.9B
Corcept Therapeutics (CORT)$5.7B
Ionis Pharmaceuticals (IONS)$5.3B
Crinetics Pharmaceuticals (CRNX)$5.1B
PTC Therapeutics (PTCT)$3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Evotec AG (EVO)$1.8B
Recursion Pharmaceuticals (RXRX)$1.8B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.5B
Indivior (INDV)$1.4B
Harrow (HROW)$1.4B
Ocular Therapeutix (OCUL)$1.4B